Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension

OBJECTIVES: The primary aim was to demonstrate that moxonidine, given in an experimental sustained release (SR) formulation, had no clinically relevant central nervous system (CNS) effects after 4 weeks of treatment. A clinically relevant CNS effect was predefined as more than 45° s(−1) reduction in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kemme, Michiel J B, Post, Jeroen P vd, Schoemaker, Rik C, Straub, Matthias, Cohen, Adam F, van Gerven, Joop M A
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2003
Assuntos:
Pharmacodynamics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884251/
https://ncbi.nlm.nih.gov/pubmed/12814444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2003.01796.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados